NuVasive Announces PMA Approval of the PCM(R) Cervical Disc System

NuVasive (NASDAQ: NUVA), a medical device company focused on developing minimallydisruptive surgical products and procedures for the spine, todayannounced that the U.S. Food and Drug Administration (FDA) hasgranted Premarket Approval (PMA) for the PCM(R) Cervical Disc System. This novel device will be provided to patients and surgeons in theUnited States as an innovative option to preserve motion in thecervical spine instead of a traditional, motion-eliminating fusionprocedure. The FDA approval comes after successful completion of aprospective, multicenter randomized investigational device exemption(IDE) clinical trial that was conducted at 23 investigational sitesacross the United States and included 403 total treated patients. Alex Lukianov, Chairman and Chief Executive Officer, said, "We arereally pleased to offer this unique technology to the U.S. surgical